Histocommon AI
Computational pathology that reads the standard H&E tumour slide with AI to predict molecular features, extracting more signal from a resource every cancer patient already has.
Platform · where we are headed
Research today, care tomorrow. Every programme here is research and development, shared for transparency and not yet clinically available.
01Where we are headed
Computational pathology that reads the standard H&E tumour slide with AI to predict molecular features, extracting more signal from a resource every cancer patient already has.
A validated computational twin of an individual’s cancer, integrating genomic, clonal, immune and clinical data, in which candidate therapies can be simulated before they are given. The fullest expression of exploring every option to find the right one faster.
A screening approach for personalised neoantigen immunotherapy, identifying the tumour-specific targets most likely to provoke an effective immune response.
Fruit-fly models engineered to carry a patient’s tumour alterations, used to rapidly test how drug combinations behave against that specific genetic makeup. A fast, scalable complement to computational prediction.
Spatial multi-omics that maps not just which cells are present in a tumour but where they sit relative to each other, revealing the immune microenvironment in place.
A privacy-preserving network that lets the engine learn across many sites without patient data ever leaving its institution. The infrastructure that lets the whole platform get smarter, safely.
The research bench behind the pipeline
02
Read the whole tumour today.
Follow it through time.
Test and map it functionally.
Bring it together, and explore every option.
Take the next step
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationCommission your decision report and a dedicated clinical team.
Explore Blueprint CareSignal replies to your first question within four hours, at no cost.
Start with Signal